Dr. Mark J. Fesler
Claim this profileSaint Luke's Hospital
Studies Lymphoma
Studies B-Cell Lymphoma
8 reported clinical trials
20 drugs studied
Area of expertise
1Lymphoma
CCND1 positive
t(11;14) positive
Stage I
2B-Cell Lymphoma
MYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Mark J. Fesler is currently running
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting2 awards Phase 3
More about Mark J. Fesler
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Mark J. Fesler has experience with
- Rituximab
- Cyclophosphamide
- Autologous Hematopoietic Stem Cell Transplantation
- Vincristine Sulfate
- Nivolumab
- Modakafusp Alfa
Breakdown of trials Mark J. Fesler has run
Lymphoma
B-Cell Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark J. Fesler specialize in?
Mark J. Fesler focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Mark J. Fesler currently recruiting for clinical trials?
Yes, Mark J. Fesler is currently recruiting for 5 clinical trials in Chesterfield Missouri. If you're interested in participating, you should apply.
Are there any treatments that Mark J. Fesler has studied deeply?
Yes, Mark J. Fesler has studied treatments such as Rituximab, Cyclophosphamide, Autologous Hematopoietic Stem Cell Transplantation.
What is the best way to schedule an appointment with Mark J. Fesler?
Apply for one of the trials that Mark J. Fesler is conducting.
What is the office address of Mark J. Fesler?
The office of Mark J. Fesler is located at: Saint Luke's Hospital, Chesterfield, Missouri 63017 United States. This is the address for their practice at the Saint Luke's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.